U.S. Markets open in 7 hrs 47 mins

EMA panel recommends that use of Actelion's Uptravi may continue

ZURICH, Feb 10 (Reuters) - A European Medicines Agency drug safety panel recommended on Friday that Actelion's Uptravi drug may continue to be used in line with current prescription information amid a probe into five deaths in France among those using the pulmonary arterial hypertension medicine.

(Reporting by John Miller; Editing by Michael Shields)